2026-09-19T13:33:02Zhttps://dspace.mit.edu/server/oai/request

oai:dspace.mit.edu:1721.1/1075202026-06-06T01:03:27Zcom_1721.1_7582com_1721.1_7581col_1721.1_131023

André Carrel. Chung, Peter Wontae Zhang, Tao Massachusetts Institute of Technology. Engineering Systems Division. Massachusetts Institute of Technology. Supply Chain Management Program 2017-03-20T19:38:09Z 2017-03-20T19:38:09Z 2016 2016 http://hdl.handle.net/1721.1/107520 962853816 Thesis: M. Eng. in Logistics, Massachusetts Institute of Technology, Supply Chain Management Program, 2016. Cataloged from PDF version of thesis. Includes bibliographical references (page 50). The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry. by Peter Wontae Chung and Tao Zhang. M.Eng. in Logistics 50 pages eng Massachusetts Institute of Technology MIT theses may be protected by copyright. Please reuse MIT thesis content according to the MIT Libraries Permissions Policy, which is available through the URL provided. http://dspace.mit.edu/handle/1721.1/7582 Supply Chain Management Program. Engineering Systems Division. A framework to evaluate interoperable data exchange models for Drug Supply Chain Security Act compliance DSCSA Thesis application/pdf false Publication unknown unknown <Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="e3ab98af-31f6-4ea6-9832-bf0ee1b43942"> <Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type> <Language>eng</Language> <Title>A framework to evaluate interoperable data exchange models for Drug Supply Chain Security Act compliance</Title> <Subtitle>DSCSA</Subtitle> <PublishedIn> <Publication> </Publication> </PublishedIn> <PublicationDate>2016</PublicationDate> <Authors> <Author> <DisplayName>Chung, Peter Wontae</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> <Author> <DisplayName>Zhang, Tao</DisplayName> <Affiliation> <OrgUnit> </OrgUnit> </Affiliation> </Author> </Authors> <Editors> </Editors> <Publishers> <Publisher> <DisplayName>Massachusetts Institute of Technology</DisplayName> <OrgUnit /> </Publisher> </Publishers> <License>http://dspace.mit.edu/handle/1721.1/7582</License> <Keyword>Supply Chain Management Program.</Keyword> <Keyword>Engineering Systems Division.</Keyword> <Abstract>The United States has one of the safest drug supply chains in the world. However, its security is threatened by new challenges such as counterfeit, diverted, and illegally imported drugs. To counter the new challenges, the Drug Supply Chain Security Act (DSCSA) was signed into law by President Obama on November 27, 2013, with a 10-year implementation timeframe. As a result, companies in the U.S. pharmaceutical industry, including drug manufacturers, distributors, and dispensers, are challenged to fully comply with the DSCSA by 2023. The compliance with the DSCSA will enable companies to operate and manage the risks of their supply chains more efficiently. Industry consortiums, such as the Healthcare Distribution Management Association (HDMA), and the industry leaders have recommended various interoperable data exchange models for the implementation of the compliance. However, domestic and international complexities make it difficult to pick the optimal model for the industry. In this research, we start with categorizing the known data exchange models that can be potentially used by the U.S. pharmaceutical industry. Second, we develop a scorecard methodology based on a framework that considers various factors across the entire supply chain. Next, we examine the categorized models using this scorecard methodology. Lastly, we conclude with recommendations on the data strategy decision for the U.S. pharmaceutical industry.</Abstract> <Access xmlns="http://purl.org/coar/access_right" > </Access> </Publication>